5-hydroxypentyl p-toluenesulfonate | 95769-37-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-hydroxypentyl p-toluenesulfonate
• 英文别名: 5-hydroxypentyl 4-methylbenzenesulfonate；5-tosyloxy-1-pentanol；1,5-pentanediol monotosylate；5-[(4-methylbenzenesulfonyl)oxy]pentan-1-ol
• CAS: 95769-37-2
• 化学式: C₁₂H₁₈O₄S
• 分子量: 258.339
• InChiKey: DDTVUXJUYZCSQN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  72
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-hydroxypentyl p-toluenesulfonate 在 fac-tris(2-phenylpyridinato-N,C2')iridium(III) 、 dipotassium hydrogenphosphate 、 草酰氯 、 二甲基亚砜 、 三乙胺 作用下， 以 二氯甲烷 、 氘代乙腈 为溶剂， 反应 39.5h， 生成 四氢呋喃-2-甲醛
  参考文献：
  名称：

  与烷氧基自由基形成分子间 C-O 键：羰基化合物的光氧化还原催化 α-烷氧基化

  摘要：

  由于烷氧基 (RO·) 自由基的高反应性及其容易发生 β 断裂或氢原子转移 (HAT) 反应的倾向，几乎没有描述涉及 RO· 自由基的分子间烷氧基化。我们在此首次报道了甲硅烷基烯醇醚对烷氧基自由基的有效分子间捕获。这种光氧化还原介导的协议能够将结构简单和更复杂的烷氧基引入范围广泛的酮和酰胺中。

  DOI：

  10.1021/acs.orglett.1c03444
• 作为产物：
  描述：

  1-戊醇,5-[(四氢-2H-吡喃-2-基)氧代]-,4-甲基苯磺酸酯 在 tetra-N-butylammonium tribromide 作用下， 以 甲醇 为溶剂， 反应 0.5h， 以93%的产率得到5-hydroxypentyl p-toluenesulfonate
  参考文献：
  名称：

  四丁基三溴化铵（TBATB）促进醇的四氢吡喃基化/去吡喃基化

  摘要：

  在室温下，在二氯甲烷中，在催化量的TBATB存在下，将酒精快速高产率地四氢吡喃化。仅通过将溶剂改为甲醇，即可定量获得脱吡喃基化为其母体醇。

  DOI：

  10.1016/s0040-4039(01)01599-4

文献信息

• Polystyrene-supported GaCl3: A new, highly efficient and recyclable heterogeneous Lewis acid catalyst for tetrahydropyranylation of alcohols and phenols
  作者：Ali Rahmatpour

  DOI：10.1016/j.poly.2012.06.063

  日期：2012.8

  highly chemoselective method for tetrahydropyranylation of alcohols and phenols with 3,4-dihydro-2H-pyran (DHP) in the presence of polystyrene-supported gallium trichloride (PS/GaCl3) as a highly active and reusable heterogeneous Lewis acid catalyst at room temperature is presented. In this catalytic system, primary, secondary and tertiary alcohols, as well as phenols, were converted to the corresponding

  在聚苯乙烯负载的三氯化镓（PS / GaCl 3）存在下，用3,4-二氢-2 H-吡喃（DHP）对醇和酚进行四氢吡喃基化的一种新的，简单且高度化学选择性的方法）是在室温下具有高活性和可重复使用的非均相路易斯酸催化剂。在该催化体系中，伯，仲和叔醇以及苯酚以短的反应时间和高收率转化为相应的四氢吡喃基（THP）醚。异质催化剂在吡喃基化反应中具有高可重复使用性和稳定性，并且被回收了数次，其活性损失可忽略不计且催化剂浸出可忽略不计，并且也不需要再生。该方法对对称二醇的单四氢吡喃基化反应也显示出良好的化学选择性。
• Pyrimidine derivatives
  申请人：Nisshin Flour Milling Co., Ltd.

  公开号：US05736550A1

  公开（公告）日：1998-04-07

  Pyrimidine derivatives useful as a gastrointestinal prokinetic agent, represented by formula ##STR1## wherein X is O or NR.sup.5, Y is O, S or NR.sup.5 wherein R.sup.5 is a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group or the like; R.sup.1 and R.sup.2 may be the same or different and each is a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group or the like; R.sup.3 is CN, or COOR.sup.6 wherein R.sup.6 is a C.sub.1 -C.sub.6 alkyl group, a C.sub.3 -C.sub.6 cycloalkyl group, an aryl group or the like; R.sup.4 is --SR.sup.7 or --NR.sup.8 R.sup.9 wherein R.sup.7 is a C.sub.1 -C.sub.6 alkyl group; R.sup.8 is a C.sub.1 -C.sub.6 alkyl group or the like; R.sup.9 is a hydrogen atom, a C.sub.1 -C.sub.6 alkyl group or the like, or R.sup.8 and R.sup.9 may represent, together with the nitrogen atom to which they are attached, an N-substituted piperazine ring of formula (X) ##STR2## wherein R.sup.10 represents a C.sub.1 -C.sub.6 alkyl group or the like or a pharmacologically acceptable salt thereof. The above-mentioned compounds are useful as a gastrointestinal prokinetic agent used for the therapy of digestive tract diseases.

  嘧啶衍生物可用作胃肠促动力药物，其化学式表示为##STR1##其中X为O或NR.sup.5，Y为O、S或NR.sup.5，其中R.sup.5为氢原子、C.sub.1 -C.sub.6烷基或类似物；R.sup.1和R.sup.2可以相同也可以不同，每个都是氢原子、C.sub.1 -C.sub.6烷基或类似物；R.sup.3为CN，或COOR.sup.6，其中R.sup.6为C.sub.1 -C.sub.6烷基、C.sub.3 -C.sub.6环烷基、芳基或类似物；R.sup.4为--SR.sup.7或--NR.sup.8 R.sup.9，其中R.sup.7为C.sub.1 -C.sub.6烷基；R.sup.8为C.sub.1 -C.sub.6烷基或类似物；R.sup.9为氢原子、C.sub.1 -C.sub.6烷基或类似物，或R.sup.8和R.sup.9可以与它们连接的氮原子一起表示为化学式(X)的N-取代哌嗪环，其中R.sup.10代表C.sub.1 -C.sub.6烷基或类似物，或其药理学上可接受的盐。上述化合物可用作治疗消化道疾病的胃肠促动力药物。
• COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR
  申请人：Arvinas, Inc.

  公开号：US20180099940A1

  公开（公告）日：2018-04-12

  The present disclosure relates to bifunctional compounds, which find utility to degrade and (inhibit) Androgen Receptor. In particular, the present disclosure is directed to compounds, which contain on one end a cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds Androgen Receptor, such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present disclosure exhibits a broad range of pharmacological activities associated with compounds according to the present disclosure, consistent with the degradation/inhibition of Androgen Receptor.

  本公开涉及双功能化合物，其用于降解和（抑制）雄激素受体。具体而言，本公开涉及包含一端结合到E3泛素连接酶的谷氨酰腺苷环配体，另一端结合到雄激素受体的部分的化合物，使得雄激素受体与泛素连接酶靠近，以实现雄激素受体的降解（和抑制）。本公开展示了与根据本公开涉及的化合物相关的广泛的药理活性范围，与雄激素受体的降解/抑制一致。
• Design and synthesis of protoporphyrin IX/vitamin<font>B₁₂</font>molecular hybrids<i>via</i><font>CuAAC</font>reaction
  作者：Rafał Loska、Anita Janiga、Dorota Gryko

  DOI：10.1142/s1088424612501350

  日期：2013.1

  The design and synthesis of new molecular hybrids composed of protoporphyrin IX (PPIX) and vitamin B₁₂via copper catalyzed alkyne azide cycloaddition reaction is described. New, clickable aminoazide and aminoalkyne linkers were prepared and subsequently attached to PPIX (via vinyl group) and to vitamin B₁₂giving desired building blocks. Preliminary results showed that respective water soluble hybrids were formed under CuAAC reaction. Gratifyingly, Cu incorporation into the PPIX core was avoided, which was important for further biological studies.

  本文介绍了通过铜催化炔吖啶环加成反应设计和合成由原卟啉 IX（PPIX）和维生素 B12 组成的新分子杂化物。研究人员制备了新的、可点击的氨基吖啶和氨基炔连接体，随后将其连接到 PPIX（通过乙烯基）和维生素 B12 上，得到了所需的构建模块。初步结果表明，在 CuAAC 反应中形成了各自的水溶性混合物。令人欣慰的是，Cu 并入 PPIX 核心的情况得以避免，这对进一步的生物研究非常重要。
• [EN] PROTEOLYSIS TARGETING CHIMERIC (PROTAC) COMPOUND WITH E3 UBIQUITIN LIGASE BINDING ACTIVITY AND TARGETING ALPHA-SYNUCLEIN PROTEIN FOR TREATING NEURODEGENERATIVE DISEASES<br/>[FR] COMPOSÉ CHIMÈRE CIBLANT LA PROTÉOLYSE (PROTAC) AYANT UNE ACTIVITÉ DE LIAISON À L'UBIQUITINE LIGASE E3 ET CIBLANT UNE PROTÉINE ALPHA-SYNUCLÉINE POUR LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES
  申请人：ARVINAS OPERATIONS INC

  公开号：WO2020041331A1

  公开（公告）日：2020-02-27

  The present disclosure relates to bifunctional compounds, which find utility as modulators of alpha-synuclein (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/ inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure. Such diseases or disorders are alpha-synucleinopathies or neurodegenerative diseases associated with alpha-synuclein accumulation and aggregation, such as e.g. Parkinson Disease, Alzheimer's Disease, dementia, dementia with Lewy bodies or multiple system atrophy, in particular Parkinson's Disease.

  本公开涉及双功能化合物，其作为α-突触核蛋白（目标蛋白）的调节剂具有实用性。具体而言，本公开涉及包含一端为Von Hippel-Lindau、cereblon、凋亡抑制蛋白或鼠双分子同源物2配体的双功能化合物，该配体与相应的E3泛素连接酶结合，另一端为与目标蛋白结合的基团，使得目标蛋白靠近泛素连接酶以促使目标蛋白的降解（和抑制）。本公开展示了与目标蛋白的降解/抑制相关的广泛药理活性范围。本公开的化合物和组合物用于治疗或预防由目标蛋白聚集或积累导致的疾病或紊乱。这些疾病或紊乱是与α-突触核蛋白积累和聚集相关的α-突触核蛋白病或神经退行性疾病，例如帕金森病、阿尔茨海默病、痴呆症、带有Lewy小体的痴呆症或多系统萎缩，特别是帕金森病。